Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
Peyrin-Biroulet L, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravatà I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Danese S. Peyrin-Biroulet L, et al. Among authors: lavie f. Aliment Pharmacol Ther. 2024 Jan;59(2):175-185. doi: 10.1111/apt.17751. Epub 2023 Nov 30. Aliment Pharmacol Ther. 2024. PMID: 38036946 Clinical Trial.
Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F, Zimmermann M, Sharaf M, Coates LC, Siebert S. Schett G, et al. Among authors: lavie f. Arthritis Res Ther. 2023 Aug 16;25(1):150. doi: 10.1186/s13075-023-03125-4. Arthritis Res Ther. 2023. PMID: 37587493 Free PMC article. Clinical Trial.
Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial.
Siebert S, Schett G, Raychaudhuri SP, Guma M, Chen W, Gao S, Chakravarty SD, Lavie F, Rahman P. Siebert S, et al. Among authors: lavie f. Ther Adv Musculoskelet Dis. 2024 Oct 27;16:1759720X241283536. doi: 10.1177/1759720X241283536. eCollection 2024. Ther Adv Musculoskelet Dis. 2024. PMID: 39493888 Free PMC article.
Hurdles in new drug development in rheumatic diseases.
Lavie F, Rooney T. Lavie F, et al. Joint Bone Spine. 2024 Jul;91(4):105672. doi: 10.1016/j.jbspin.2023.105672. Epub 2023 Nov 30. Joint Bone Spine. 2024. PMID: 38042361 Free article. Review.
Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F, Zimmermann M, Sharaf M, Coates LC, Siebert S. Schett G, et al. Among authors: lavie f. Arthritis Res Ther. 2023 Sep 15;25(1):170. doi: 10.1186/s13075-023-03158-9. Arthritis Res Ther. 2023. PMID: 37715280 Free PMC article. No abstract available.
Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial.
McInnes IB, Sewerin P, Sharaf M, Efficace M, Lavie F, Zimmermann M, Coates LC. McInnes IB, et al. Among authors: lavie f. RMD Open. 2024 Dec 12;10(4):e004494. doi: 10.1136/rmdopen-2024-004494. RMD Open. 2024. PMID: 39672591 Free PMC article. Clinical Trial.
Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS.
Gossec L, Baraliakos X, Aletaha D, Sharaf M, Rampakakis E, Lavie F, López-Medina C, Selmi C, Coates LC. Gossec L, et al. Among authors: lavie f. Rheumatology (Oxford). 2024 Oct 22:keae586. doi: 10.1093/rheumatology/keae586. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39437003
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
Siebert S, Coates LC, Schett G, Raychaudhuri SP, Chen W, Gao S, Seridi L, Chakravarty SD, Shawi M, Lavie F, Sharaf M, Zimmermann M, Kollmeier AP, Xu XL, Rahman P, Mease PJ, Deodhar A. Siebert S, et al. Among authors: lavie f. Arthritis Rheumatol. 2024 Jun;76(6):894-904. doi: 10.1002/art.42803. Epub 2024 Mar 4. Arthritis Rheumatol. 2024. PMID: 38253404 Clinical Trial.
51 results